FAAH inhibitor 1 is primarily used in research settings to study the endocannabinoid system and its role in various physiological processes. By inhibiting the enzyme fatty acid amide hydrolase (FAAH), it increases the levels of endocannabinoids like anandamide, which play a key role in regulating pain, inflammation, mood, and appetite. This compound is valuable in preclinical studies aimed at understanding the therapeutic potential of FAAH inhibition in conditions such as chronic pain, anxiety, depression, and neurodegenerative disorders. Additionally, it serves as a tool for investigating the mechanisms underlying the endocannabinoid system and its interactions with other signaling pathways.